Flubendazole

Flubendazole is a benzimidazole carbamate anthelmintic.¹ It completely eliminates larvae in a mouse model of A. cantonensis infection and exhibits a mean larval reduction of 100% in a T. spiralis infection model when administered at doses of 5 and 50 mg/kg per day, respectively.² Flubendazole inhibits mammalian tubulin polymerization (IC₅₀ = 2.5 µM) and inhibits binding of [³H]mebendazole to H. contortus L3 larval tubulin (IC₅₀ = 0.17 µM).³ Flubendazole also inhibits the proliferation of BT-549, SK-BR-3, MDA-MB-231, and MCF-7 breast cancer cells (IC₅₀s = 0.72, 1.51, 1.75, and 5.51 µM, respectively) and reduces tumor growth in an MDA-MB-231 mouse xenograft model when administered at a dose of 25 mg/kg.⁴

WARNING This product is not for human or veterinary use.

1. Čáňová, K., Rozkydalová, L., and Rudolf, E. Anthelmintic flubendazole and its potential use in anticancer therapy. Acta Medica (Hradec Kralove) 60(1), 5-11 (2017).

2. Maki, J., and Yanagisawa, T. A comparison of the effects of flubendazole and thiabendazole on the larvae of Angiostrongylus cantonensis, Trichinella spiralis, Diphyllobothrium erinacei and Hymenolepis nana in mice. Parasitology 87(Pt 3), 525-531 (1983).

3. Lacey, E. Mode of action of benzimidazoles. Parasitol. Today 6(4), 112-115 (1990).

4. Hou, Z.-J., Lou, X., Zhang, W., et al. Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells. Oncotarget 6(8), 6326-6340 (2015).